A balanced randomised placebo controlled blinded phase IIa multi-centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: The QUIET-1 trial. (2019)
Attributed to:
Biomedical Catalyst – Clinical proof of concept trial of a Kv3 modulator for the treatment of tinnitus
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.heares.2019.03.018
PubMed Identifier: 30939361
Publication URI: http://europepmc.org/abstract/MED/30939361
Type: Journal Article/Review
Volume: 377
Parent Publication: Hearing research
ISSN: 0378-5955